 | • レポートコード：GIR-105X14219 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、遺伝子組換え型血漿タンパク質治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。遺伝子組換え型血漿タンパク質治療薬の種類別市場規模（遺伝子組換え型凝固因子、ヒトC1エステラーゼ阻害剤）、用途別市場規模（血友病A、血友病B、フォンウィルブランド病）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・遺伝子組換え型血漿タンパク質治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：CSL Limited、Takeda、Octapharma、Novo Nordisk A/S、Pfizer、Bioverativ Therapeutics、Aptevo Therapeutics、Pharming Group ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：遺伝子組換え型凝固因子、ヒトC1エステラーゼ阻害剤 ・用途別分析2016年-2026年：血友病A、血友病B、フォンウィルブランド病 ・遺伝子組換え型血漿タンパク質治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・遺伝子組換え型血漿タンパク質治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・遺伝子組換え型血漿タンパク質治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・遺伝子組換え型血漿タンパク質治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・遺伝子組換え型血漿タンパク質治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Recombinant Plasma Protein Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Recombinant Plasma Protein Therapeutics size is estimated to be xx million in 2020 from USD 7917.8 million in 2019, with a change of XX% between 2019 and 2020. The global Recombinant Plasma Protein Therapeutics market size is expected to grow at a CAGR of 4.7% for the next five years.
Market segmentation
Recombinant Plasma Protein Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Recombinant Coagulation Factors
Human C1 Esterase Inhibitor
Market segment by Application can be divided into
Hemophilia A
Hemophilia B
Von Willebrand Disease
The key market players for global Recombinant Plasma Protein Therapeutics market are listed below:
CSL Limited
Takeda
Octapharma
Novo Nordisk A/S
Pfizer
Bioverativ Therapeutics
Aptevo Therapeutics
Pharming Group
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Recombinant Plasma Protein Therapeutics Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Recombinant Plasma Protein Therapeutics Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Recombinant Coagulation Factors
1.2.3 Human C1 Esterase Inhibitor
1.3 Market Analysis by Application
1.3.1 Overview: Global Recombinant Plasma Protein Therapeutics Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hemophilia A
1.3.3 Hemophilia B
1.3.4 Von Willebrand Disease
1.4 Global Recombinant Plasma Protein Therapeutics Market Size & Forecast
1.4.1 Global Recombinant Plasma Protein Therapeutics Sales in Value (2016-2026))
1.4.2 Global Recombinant Plasma Protein Therapeutics Sales in Volume (2016-2026)
1.4.3 Global Recombinant Plasma Protein Therapeutics Price by Type (2016-2026) & (USD/Unit)
1.5 Global Recombinant Plasma Protein Therapeutics Production Capacity Analysis
1.5.1 Global Recombinant Plasma Protein Therapeutics Total Production Capacity (2016-2026)
1.5.2 Global Recombinant Plasma Protein Therapeutics Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Recombinant Plasma Protein Therapeutics Market Drivers
1.6.2 Recombinant Plasma Protein Therapeutics Market Restraints
1.6.3 Recombinant Plasma Protein Therapeutics Trends Analysis
2 Manufacturers Profiles
2.1 CSL Limited
2.1.1 CSL Limited Details
2.1.2 CSL Limited Major Business
2.1.3 CSL Limited Recombinant Plasma Protein Therapeutics Product and Services
2.1.4 CSL Limited Recombinant Plasma Protein Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Takeda
2.2.1 Takeda Details
2.2.2 Takeda Major Business
2.2.3 Takeda Recombinant Plasma Protein Therapeutics Product and Services
2.2.4 Takeda Recombinant Plasma Protein Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Octapharma
2.3.1 Octapharma Details
2.3.2 Octapharma Major Business
2.3.3 Octapharma Recombinant Plasma Protein Therapeutics Product and Services
2.3.4 Octapharma Recombinant Plasma Protein Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Novo Nordisk A/S
2.4.1 Novo Nordisk A/S Details
2.4.2 Novo Nordisk A/S Major Business
2.4.3 Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Product and Services
2.4.4 Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Recombinant Plasma Protein Therapeutics Product and Services
2.5.4 Pfizer Recombinant Plasma Protein Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Bioverativ Therapeutics
2.6.1 Bioverativ Therapeutics Details
2.6.2 Bioverativ Therapeutics Major Business
2.6.3 Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Product and Services
2.6.4 Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 Aptevo Therapeutics
2.7.1 Aptevo Therapeutics Details
2.7.2 Aptevo Therapeutics Major Business
2.7.3 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Product and Services
2.7.4 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.8 Pharming Group
2.8.1 Pharming Group Details
2.8.2 Pharming Group Major Business
2.8.3 Pharming Group Recombinant Plasma Protein Therapeutics Product and Services
2.8.4 Pharming Group Recombinant Plasma Protein Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Recombinant Plasma Protein Therapeutics Sales by Manufacturer
3.1 Global Recombinant Plasma Protein Therapeutics Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Recombinant Plasma Protein Therapeutics Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Recombinant Plasma Protein Therapeutics
3.4 Market Concentration Rate
3.4.1 Top 3 Recombinant Plasma Protein Therapeutics Manufacturer Market Share
3.4.2 Top 6 Recombinant Plasma Protein Therapeutics Manufacturer Market Share
3.5 Global Recombinant Plasma Protein Therapeutics Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Recombinant Plasma Protein Therapeutics Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Recombinant Plasma Protein Therapeutics Market Size by Region
4.1.1 Global Recombinant Plasma Protein Therapeutics Sales in Volume by Region (2016-2026)
4.1.2 Global Recombinant Plasma Protein Therapeutics Revenue by Region (2016-2026)
4.2 North America Recombinant Plasma Protein Therapeutics Revenue (2016-2026)
4.3 Europe Recombinant Plasma Protein Therapeutics Revenue (2016-2026)
4.4 Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue (2016-2026)
4.5 South America Recombinant Plasma Protein Therapeutics Revenue (2016-2026)
4.6 Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Recombinant Plasma Protein Therapeutics Sales in Volume by Type (2016-2026)
5.2 Global Recombinant Plasma Protein Therapeutics Revenue by Type (2016-2026)
5.3 Global Recombinant Plasma Protein Therapeutics Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Recombinant Plasma Protein Therapeutics Sales in Volume by Application (2016-2026)
6.2 Global Recombinant Plasma Protein Therapeutics Revenue by Application (2016-2026)
6.3 Global Recombinant Plasma Protein Therapeutics Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Recombinant Plasma Protein Therapeutics Sales by Type (2016-2026)
7.2 North America Recombinant Plasma Protein Therapeutics Sales by Application (2016-2026)
7.3 North America Recombinant Plasma Protein Therapeutics Market Size by Country
7.3.1 North America Recombinant Plasma Protein Therapeutics Sales in Volume by Country (2016-2026)
7.3.2 North America Recombinant Plasma Protein Therapeutics Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Recombinant Plasma Protein Therapeutics Sales by Type (2016-2026)
8.2 Europe Recombinant Plasma Protein Therapeutics Sales by Application (2016-2026)
8.3 Europe Recombinant Plasma Protein Therapeutics Market Size by Country
8.3.1 Europe Recombinant Plasma Protein Therapeutics Sales in Volume by Country (2016-2026)
8.3.2 Europe Recombinant Plasma Protein Therapeutics Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Type (2016-2026)
9.2 Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Application (2016-2026)
9.3 Asia-Pacific Recombinant Plasma Protein Therapeutics Market Size by Region
9.3.1 Asia-Pacific Recombinant Plasma Protein Therapeutics Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Recombinant Plasma Protein Therapeutics Sales by Type (2016-2026)
10.2 South America Recombinant Plasma Protein Therapeutics Sales by Application (2016-2026)
10.3 South America Recombinant Plasma Protein Therapeutics Market Size by Country
10.3.1 South America Recombinant Plasma Protein Therapeutics Sales in Volume by Country (2016-2026)
10.3.2 South America Recombinant Plasma Protein Therapeutics Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Recombinant Plasma Protein Therapeutics Sales by Type (2016-2026)
11.2 Middle East & Africa Recombinant Plasma Protein Therapeutics Sales by Application (2016-2026)
11.3 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Size by Country
11.3.1 Middle East & Africa Recombinant Plasma Protein Therapeutics Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Recombinant Plasma Protein Therapeutics Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Recombinant Plasma Protein Therapeutics Typical Distributors
12.3 Recombinant Plasma Protein Therapeutics Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Recombinant Plasma Protein Therapeutics Revenue by Type, (USD Million), 2021-2026
Table 2. Global Recombinant Plasma Protein Therapeutics Revenue by Application, (USD Million), 2021-2026
Table 3. CSL Limited Basic Information, Manufacturing Base and Competitors
Table 4. CSL Limited Major Business
Table 5. CSL Limited Recombinant Plasma Protein Therapeutics Product and Services
Table 6. CSL Limited Recombinant Plasma Protein Therapeutics Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Takeda Basic Information, Manufacturing Base and Competitors
Table 8. Takeda Major Business
Table 9. Takeda Recombinant Plasma Protein Therapeutics Product and Services
Table 10. Takeda Recombinant Plasma Protein Therapeutics Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Octapharma Basic Information, Manufacturing Base and Competitors
Table 12. Octapharma Major Business
Table 13. Octapharma Recombinant Plasma Protein Therapeutics Product and Services
Table 14. Octapharma Recombinant Plasma Protein Therapeutics Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Novo Nordisk A/S Basic Information, Manufacturing Base and Competitors
Table 16. Novo Nordisk A/S Major Business
Table 17. Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Product and Services
Table 18. Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Pfizer Basic Information, Manufacturing Base and Competitors
Table 20. Pfizer Major Business
Table 21. Pfizer Recombinant Plasma Protein Therapeutics Product and Services
Table 22. Pfizer Recombinant Plasma Protein Therapeutics Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Bioverativ Therapeutics Basic Information, Manufacturing Base and Competitors
Table 24. Bioverativ Therapeutics Major Business
Table 25. Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Product and Services
Table 26. Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Aptevo Therapeutics Basic Information, Manufacturing Base and Competitors
Table 28. Aptevo Therapeutics Major Business
Table 29. Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Product and Services
Table 30. Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Pharming Group Basic Information, Manufacturing Base and Competitors
Table 32. Pharming Group Major Business
Table 33. Pharming Group Recombinant Plasma Protein Therapeutics Product and Services
Table 34. Pharming Group Recombinant Plasma Protein Therapeutics Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Global Recombinant Plasma Protein Therapeutics Sales by Manufacturer (2019-2021e) & (K Units)
Table 36. Global Recombinant Plasma Protein Therapeutics Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 37. Market Position of Manufacturers in Recombinant Plasma Protein Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 38. Global Recombinant Plasma Protein Therapeutics Production Capacity by Company, (K Units): 2020 VS 2021
Table 39. Head Office and Recombinant Plasma Protein Therapeutics Production Site of Key Manufacturer
Table 40. Global Recombinant Plasma Protein Therapeutics Sales by Region (2016-2021e) & (K Units)
Table 41. Global Recombinant Plasma Protein Therapeutics Sales by Region (2021-2026) & (K Units)
Table 42. Global Recombinant Plasma Protein Therapeutics Revenue by Region (2016-2021e) & (USD Million)
Table 43. Global Recombinant Plasma Protein Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 44. Global Recombinant Plasma Protein Therapeutics Sales by Type (2016-2021e) & (K Units)
Table 45. Global Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (K Units)
Table 46. Global Recombinant Plasma Protein Therapeutics Revenue by Type (2016-2021e) & (USD Million)
Table 47. Global Recombinant Plasma Protein Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 48. Global Recombinant Plasma Protein Therapeutics Price by Type (2016-2021e) & (USD/Unit)
Table 49. Global Recombinant Plasma Protein Therapeutics Price by Type (2021-2026) & (USD/Unit)
Table 50. Global Recombinant Plasma Protein Therapeutics Sales by Application (2016-2021e) & (K Units)
Table 51. Global Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (K Units)
Table 52. Global Recombinant Plasma Protein Therapeutics Revenue by Application (2016-2021e) & (USD Million)
Table 53. Global Recombinant Plasma Protein Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 54. Global Recombinant Plasma Protein Therapeutics Price by Application (2016-2021e) & (USD/Unit)
Table 55. Global Recombinant Plasma Protein Therapeutics Price by Application (2021-2026) & (USD/Unit)
Table 56. North America Recombinant Plasma Protein Therapeutics Sales by Country (2016-2021e) & (K Units)
Table 57. North America Recombinant Plasma Protein Therapeutics Sales by Country (2021-2026) & (K Units)
Table 58. North America Recombinant Plasma Protein Therapeutics Revenue by Country (2016-2021e) & (USD Million)
Table 59. North America Recombinant Plasma Protein Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 60. North America Recombinant Plasma Protein Therapeutics Sales by Type (2016-2021e) & (K Units)
Table 61. North America Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (K Units)
Table 62. North America Recombinant Plasma Protein Therapeutics Sales by Application (2016-2021e) & (K Units)
Table 63. North America Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (K Units)
Table 64. Europe Recombinant Plasma Protein Therapeutics Sales by Country (2016-2021e) & (K Units)
Table 65. Europe Recombinant Plasma Protein Therapeutics Sales by Country (2021-2026) & (K Units)
Table 66. Europe Recombinant Plasma Protein Therapeutics Revenue by Country (2016-2021e) & (USD Million)
Table 67. Europe Recombinant Plasma Protein Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 68. Europe Recombinant Plasma Protein Therapeutics Sales by Type (2016-2021e) & (K Units)
Table 69. Europe Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (K Units)
Table 70. Europe Recombinant Plasma Protein Therapeutics Sales by Application (2016-2021e) & (K Units)
Table 71. Europe Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (K Units)
Table 72. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Region (2016-2021e) & (K Units)
Table 73. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Region (2021-2026) & (K Units)
Table 74. Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue by Region (2016-2021e) & (USD Million)
Table 75. Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 76. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Type (2016-2021e) & (K Units)
Table 77. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (K Units)
Table 78. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Application (2016-2021e) & (K Units)
Table 79. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (K Units)
Table 80. South America Recombinant Plasma Protein Therapeutics Sales by Country (2016-2021e) & (K Units)
Table 81. South America Recombinant Plasma Protein Therapeutics Sales by Country (2021-2026) & (K Units)
Table 82. South America Recombinant Plasma Protein Therapeutics Revenue by Country (2016-2021e) & (USD Million)
Table 83. South America Recombinant Plasma Protein Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 84. South America Recombinant Plasma Protein Therapeutics Sales by Type (2016-2021e) & (K Units)
Table 85. South America Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (K Units)
Table 86. South America Recombinant Plasma Protein Therapeutics Sales by Application (2016-2021e) & (K Units)
Table 87. South America Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (K Units)
Table 88. Middle East & Africa Recombinant Plasma Protein Therapeutics Sales by Country (2016-2021e) & (K Units)
Table 89. Middle East & Africa Recombinant Plasma Protein Therapeutics Sales by Country (2021-2026) & (K Units)
Table 90. Middle East & Africa Recombinant Plasma Protein Therapeutics Revenue by Country (2016-2021e) & (USD Million)
Table 91. Middle East & Africa Recombinant Plasma Protein Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 92. Middle East & Africa Recombinant Plasma Protein Therapeutics Sales by Type (2016-2021e) & (K Units)
Table 93. Middle East & Africa Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (K Units)
Table 94. Middle East & Africa Recombinant Plasma Protein Therapeutics Sales by Application (2016-2021e) & (K Units)
Table 95. Middle East & Africa Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (K Units)
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. Recombinant Plasma Protein Therapeutics Typical Distributors
Table 99. Recombinant Plasma Protein Therapeutics Typical Customers
List of Figures
Figure 1. Recombinant Plasma Protein Therapeutics Picture
Figure 2. Global Recombinant Plasma Protein Therapeutics Sales Market Share by Type in 2020
Figure 3. Recombinant Coagulation Factors
Figure 4. Human C1 Esterase Inhibitor
Figure 5. Global Recombinant Plasma Protein Therapeutics Sales Market Share by Application in 2020
Figure 6. Hemophilia A
Figure 7. Hemophilia B
Figure 8. Von Willebrand Disease
Figure 9. Global Recombinant Plasma Protein Therapeutics Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 10. Global Recombinant Plasma Protein Therapeutics Market Size and Forecast (2016-2026) & (USD Million)
Figure 11. United States Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 12. Canada Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 13. Mexico Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 14. Germany Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. France Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. United Kingdom Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. Russia Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Italy Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. China Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. Japan Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. Korea Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. India Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. Southeast Asia Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Australia Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Brazil Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Egypt Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Saudi Arabia Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. South Africa Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Turkey Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Global Recombinant Plasma Protein Therapeutics Sales (2016-2026) & (K Units)
Figure 31. Global Recombinant Plasma Protein Therapeutics Production Capacity (2016-2026) & (K Units)
Figure 32. Global Recombinant Plasma Protein Therapeutics Production Capacity by Geographic Region: 2020 VS 2021
Figure 33. Recombinant Plasma Protein Therapeutics Market Drivers
Figure 34. Recombinant Plasma Protein Therapeutics Market Restraints
Figure 35. Recombinant Plasma Protein Therapeutics Market Trends
Figure 36. Global Recombinant Plasma Protein Therapeutics Sales Market Share by Manufacturer in 2020
Figure 37. Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Manufacturer in 2020
Figure 38. Recombinant Plasma Protein Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 39. Top 3 Recombinant Plasma Protein Therapeutics Manufacturer (Revenue) Market Share in 2020
Figure 40. Top 6 Recombinant Plasma Protein Therapeutics Manufacturer (Revenue) Market Share in 2020
Figure 41. Global Recombinant Plasma Protein Therapeutics Sales Market Share by Region (2016-2026)
Figure 42. Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Region (2016-2026)
Figure 43. North America Recombinant Plasma Protein Therapeutics Revenue (2016-2026) & (USD Million)
Figure 44. Europe Recombinant Plasma Protein Therapeutics Revenue (2016-2026) & (USD Million)
Figure 45. Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue (2016-2026) & (USD Million)
Figure 46. South America Recombinant Plasma Protein Therapeutics Revenue (2016-2026) & (USD Million)
Figure 47. Middle East & Africa Recombinant Plasma Protein Therapeutics Revenue (2016-2026) & (USD Million)
Figure 48. Global Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2016-2026)
Figure 49. Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Type (2016-2026)
Figure 50. Global Recombinant Plasma Protein Therapeutics Price by Type (2016-2026) & (USD/Unit)
Figure 51. Global Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2016-2026)
Figure 52. Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Application (2016-2026)
Figure 53. Global Recombinant Plasma Protein Therapeutics Price by Application (2016-2026) & (USD/Unit)
Figure 54. North America Recombinant Plasma Protein Therapeutics Sales Market Share by Country (2016-2026)
Figure 55. North America Recombinant Plasma Protein Therapeutics Revenue Market Share by Country (2016-2026)
Figure 56. North America Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2016-2026)
Figure 57. North America Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2016-2026)
Figure 58. Europe Recombinant Plasma Protein Therapeutics Sales Market Share by Country (2016-2026)
Figure 59. Europe Recombinant Plasma Protein Therapeutics Revenue Market Share by Country (2016-2026)
Figure 60. Europe Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2016-2026)
Figure 61. Europe Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2016-2026)
Figure 62. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Market Share by Region (2016-2026)
Figure 63. Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue Market Share by Region (2016-2026)
Figure 64. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Market Share by Region (2016-2026)
Figure 65. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2016-2026)
Figure 66. South America Recombinant Plasma Protein Therapeutics Sales Market Share by Country (2016-2026)
Figure 67. South America Recombinant Plasma Protein Therapeutics Revenue Market Share by Country (2016-2026)
Figure 68. South America Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2016-2026)
Figure 69. South America Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2016-2026)
Figure 70. Middle East & Africa Recombinant Plasma Protein Therapeutics Sales Market Share by Country (2016-2026)
Figure 71. Middle East & Africa Recombinant Plasma Protein Therapeutics Revenue Market Share by Country (2016-2026)
Figure 72. Middle East & Africa Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2016-2026)
Figure 74. Sales Channel: Direct Channel vs Indirect Channel
Figure 75. Methodology
Figure 76. Research Process and Data Source
ペグ化タンパク質治療の世界市場予測 2023年：メーカー別、地域別、種類・用途別 PEGylation is the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to molecules, such as a drug, therapeutic protein, or vesicle. PEGylated protein therapeutics is estimated to show significant market growth during the forecast period, majorly due to the, growth …- 世界の遺伝子組換え型タンパク質ワクチン市場 2021：企業別、地域別、種類・用途別 The Recombinant Protein Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade reg…
- 組み換え治療用抗体とタンパク質の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specific…
- 組み換え凝固因子の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Recombinant coagulation factors are plasma derived counterparts used to treat infection from viruses such as hepatitis C and the human immunodeficiency virus. In addition, recombinant coagulation factors have low risk for transmission of infectious agents. Scope of the Report: This report studies th…
- プラズマ治療の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Plasma, pale yellow in color, is the component of the blood. Scope of the Report: This report focuses on the Plasma Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, r…